Phasei Program News Today

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Debra L. Richardson, MD, FACS, FACOG, discusses the safety profile of upifitamab rilsodotin in the phase 1/2 UPLIFT trial of patients with ovarian cancer.

Debra L. Richardson, MD, FACS, FACOG, discusses outcomes seen with upifitamab rilsodotin in the phase 1/2 UPLIFT trial for patients with ovarian cancer.

Debra L. Richardson, MD, FACS, FACOG, expands on results with upifitamab rilsodotin in platinum-resistant high-grade serous ovarian cancer.

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

TORONTO & SAN FRANCISCO, February 14, 2024--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the company’s pipeline of small molecules, biologics and cell therapies.

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.